Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mirvetuximab Soravtansine + SL-172154 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mirvetuximab Soravtansine | Elahere | IMGN853|M9346A-sulfo-SPDB-DM4|mirvetuximab soravtansine-gynx | FOLR1-targeted Therapy 24 | Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate comprised of an antibody directed against FOLR1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506). Elahere (mirvetuximab soravtansine) is FDA approved for use in patients with FOLR1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatments (FDA.gov). |
SL-172154 | SL172154|SL 172154|CD172a-Fc-CD40L Chimeric Protein SL-172154 | SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05483933 | Phase I | Pegylated liposomal doxorubicin + SL-172154 Mirvetuximab Soravtansine + SL-172154 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | Completed | USA | GBR | ESP | CAN | 0 |